Needham and Co's report in November before last weeks results, stated the potential for Pimavanserin is $1.5 Billion +
" We believe PDP represents an attractive commercial opportunity for
a company with a small sales force. Notably, however, Acadia has
also previously shown utility of pimavanserin in schizophrenia in a
Phase 2 trial. We believe the market potential in PDP may be
~$500M and over $1B in schizophrenia. Acadia may also explore
efficacy in Alzheimer’s disease psychosis.
• We conservatively assume another 2 years to conduct Study 021,
which would allow for a commercial launch in 2016. Study 021 may
enroll more quickly than Study 020.
Sentiment: Strong Buy
very cheap here
I Am In.
on the way to $10